A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis

NCT01915914 | Completed Phase 4 Results

• 1 other identifier: 117291
• Study Type: interventional
• Target: 107
• Locations: 1 country
• Sites: 4

Brief Summary

This is an open-label, randomized, comparative study, including 4 phases: SCREENING, ACUTE, MAINTENANCE and FOLLOW-UP. Subjects will complete the SCREENING phase to check the eligibility within 7 days after they sign the written informed consent form. All eligible subjects will be enrolled in ACUTE phase to receive twice daily Fluticasone propionate (FP) 0.05% cream up to 4 weeks. The efficacy and safety in ACUTE phase will be assessed every 2 weeks up to 4 weeks or until Treatment Success which depends on which time point comes first. Then subject can get into the MAINTENANCE phase receiving either emollient twice daily plus FP 0.05% cream once daily twice a week (Group A), or emollient twice daily (Group B), by 1:1 randomization. The treatment duration in MAINTENANCE phase will be up to 20 weeks. The efficacy and safety in MAINTENANCE phase will be assessed every 4 weeks up to 20 weeks or until AD relapse that depends on which time point comes first. If subjects don't experience relapse during MAINTENANCE phase, subsequent FOLLOW-UP phase applying emollient twice daily won't be longer than another 12 weeks. Total study duration is up to 37 weeks. All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient twice daily up to 12 weeks. This study will enrol 120 subjects, and propose at least 80 subjects to be randomized. Study Endpoints/Assessments: Primary endpoint is to observe the median time to the first relapse of AD during MAINTENANCE phase. Secondary endpoints are:

1. 1.Median time to the first relapse of AD during the whole study (including maintenance phase and follow-up phase.
2. 2.Numbers of recurrent patients at the end of MAINTENANCE phase;
3. 3.Numbers of recurrent patients at the end of FOLLOW-UP phase;
4. 4.The effective rates (proportion of "treatment success" patients) during ACUTE phase (V3, W-2±2days;V4, W0±2days )
5. 5.Evaluate the safety during the whole study duration (ACUTE phase, MAINTENANCE phase, FOLLOW-UP phase respectively);
6. 6.Evaluate visual skin assessment for signs of cutaneous atrophy, epidermal thickening / lichenification and abnormal pigmentation changes during the whole study duration (ACUTE phase, MAINTENANCE phase, FOLLOW-UP phase respectively);
7. 7.The change of Quality of Life (QoL) from baseline at the end of MAINTENANCE phase;
8. 8.The change of Quality of Life (QoL) from baseline at the end of FOLLOW-UP phase;
9. 9.Subjects' post-study evaluation to drugs.

Conditions

Skin Diseases

Outcome Measures

Primary Outcomes (1)

• Time to the First Relapse of AD During the Maintenance Phase

  Time to the first relapse of AD is defined as the number of days from start of the FP treatment in Maintenance Phase until AD relapse. AD relapse is defined as participants with PSGA exacerbation score \>=2 (the six-point scale of PSGA score range from 0 to 5 where 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5=very severe) compared to PSGA score of treatment success during Acute Phase. Participants with treatment success are defined as participants with PSGA \<=1; and the improvement \>=2 compared to Baseline.

  From the start of treatment up to Week 20 during the Maintenance Phase

Secondary Outcomes (11)

• Median Time to the First Relapse of AD During the Maintenance Phase and Follow-up Phase

  From the start of treatment up to Week 32 during the Maintenance Phase and Follow-up Phase

• Numbers of Recurrent Participants at the End of the Maintenance Phase (Week 20)

  From Week 0 (or treatment success, if earlier) to Week 20

• Numbers of Recurrent Participants at the End of the Follow-up Phase (Week 32)

  From Week 20 to Week 32

• Number of Participants With "Treatment Success" During the Acute Phase

  From the start of treatment up to Visit 4 (Week 0) or treatment success (depends on which time point comes first)

• Change From Baseline in Quality of Life (QoL) at the End of the Maintenance Phase

  Baseline and Week 20

Study Arms (2)

fluticasone propionate

EXPERIMENTAL

To evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream (twice per week) in reducing the risk of relapse when added to regular daily moisturization using PHYSIOGEL Lotion in paediatric subjects with stabilized atopic dermatitis

Drug: Fluticasone propionate

physiogel

ACTIVE COMPARATOR

To compare the efficacy and safety of fluticasone propionate 0.05% cream (twice per week) added to regular daily moisturization using Physiogel Lotion with Physiogel Lotion alone in paediatric subjects with stabilized atopic dermatitis

Drug: Fluticasone propionate

Interventions

Fluticasone propionate DRUG

All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.

fluticasone propionate; physiogel

Eligibility Criteria

• Age: 1 Year - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Specific information regarding warnings, precautions, contraindications, adverse events, and other pertinent information on the GSK investigational product or other study treatment that may impact subject eligibility is provided in the package insert of CUTIVATE and PHYSIOGEL Lotion.
• male or female patients age between 1 to 18 years old (including 1 year and excluding 18 years old);
• Diagnose atopic dermatitis according to criteria of Williams;
• Mild to moderate AD on the head/neck, trunk, upper limbs or lower limbs and PSGA scores 2-3;
• The informed consent must be signed before any study specific tests or procedures are initiated;
• Subjects eligible for enrolment in the MAINTENANCE phase of the study must meet all of the following criteria:
• Achieve treatment success after receiving Fluticasone propionate 0.05% cream twice daily up to 4 weeks in ACUTE phase

You may not qualify if:

• Subjects meeting any of the following criteria must not be enrolled in the study:
• Acute phase:
• Dermatitis of only the face, feet or hands;
• The involved area has exceeded 10% of the whole body area;
• Diagnosed contact dermatitis at predilection sites of AD;
• Atrophy, telangiectasia, extensive scarring lesions in the area or areas to be treated;
• Had topical therapies including but not limit to calcineurin inhibitors (topical tacrolimus or topical pimecrolimus), corticosteroids, antihistamines within 14 days prior to screening;
• Has accepted nonsteroidal immunosuppressants (eg cyclosporine, methotrexate), or ultraviolet light treatments including ultraviolet-A and ultraviolet-B, or systemic corticosteroids regardless administration by oral, intramuscular, or intravenous within 4 weeks prior to screening;
• Pregnant or breast-feeding. Women of Childbearing Potential (WOCBP) with a positive urine pregnancy test performed within 7 days before the start of treatment;
• Has immunocompromised disease (e.g. lymphoma, AIDS, Wiskott-Aldrich syndrome) or have a history of malignancy (including basal cell carcinoma, squamous cell carcinoma, melanoma);
• Has open skin infections (bacterial, viral or fungal) if at the application site;
• Has head lice or scabies;
• Present with clinical conditions other than AD that may interfere with the valuation (e.g. generalized erythrodema, toxicoderma, acne, Netherton's Syndrome, psoriasis);
• Require systemic therapy for the treatment of atopic dermatitis, or had systemic therapy including but not limit to antihistamines within 14 days prior to screening;
• Has accepted any experimental or investigational drug or therapy within 6 weeks prior to screening;

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (4)

GSK Investigational Site

Shenzhen, Guangdong, 518038, China

Location

GSK Investigational Site

Changsha, Hunan, 410007, China

Location

GSK Investigational Site

Beijing, China

Location

GSK Investigational Site

Shanghai, 200092, China

Location

MeSH Terms

Conditions

Skin Diseases

Interventions

Fluticasone

Condition Hierarchy (Ancestors)

Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Androstadienes; Androstenes; Androstanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 27, 2013
• First Posted: August 5, 2013
• Study Start: December 23, 2013
• Primary Completion: February 15, 2015
• Study Completion: February 15, 2015
• Last Updated: October 12, 2018
• Results First Posted: December 23, 2015

Record last verified: 2018-09

Locations

CN (4)